Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome, Inc. (Nasdaq: IMNM) announced promising results from its COVID-19 antibody cocktail, IMM-BCP-01, which effectively neutralized the Omicron variant in in vivo studies with hamsters. The antibody IMM20253 also showed effectiveness against the BA.2 subvariant in in vitro tests. The research indicates that the cocktail retains substantial activity against various Omicron subvariants, enhancing confidence in their Phase 1b study. The study is supported by the U.S. Department of Defense.
Immunome, Inc. (Nasdaq: IMNM) reported its Q1 2022 financial results, highlighting FDA clearance for its Phase 1b clinical trial of the COVID-19 antibody cocktail, IMM-BCP-01. This therapy aims to address the urgent need for effective COVID-19 treatments amid new variants. The company also progresses its IL-38 targeting antibody treatment, IMM-ONC-01, with an IND submission planned for late 2022. Financially, R&D expenses were $8.1 million, G&A expenses were $3.6 million, and a net loss of $11.7 million was recorded. Cash reserves stood at $42.9 million as of March 31, 2022.
Immunome, Inc. (Nasdaq: IMNM) has received a safe-to-proceed notification from the U.S. FDA for its IMM-BCP-01 investigational new drug application, allowing progress towards a Phase 1b clinical trial. The company’s antibody cocktail has shown promising in vitro efficacy against the Omicron variant of COVID-19, neutralizing it with significantly higher potency than existing treatments. Financially, Immunome reported a net loss of $7.9M for Q4 2021, with cash reserves of $49.2M as of December 31, 2021. Ongoing projects include the development of IMM-ONC-01 for targeting IL-38 in oncology.
Immunome, Inc. (NASDAQ: IMNM) has announced that the FDA has lifted the clinical hold on its Investigational New Drug (IND) application for the antibody cocktail IMM-BCP-01, aimed at treating COVID-19. The hold was previously placed due to requests for additional information regarding the drug's preparation and administration. Immunome provided a comprehensive report to address these concerns. The company plans to initiate a placebo-controlled dose escalation study for IMM-BCP-01, which utilizes a three-antibody cocktail targeting the SARS-CoV-2 Spike protein.
Immunome (NASDAQ: IMNM) announced positive in vitro results for its antibody cocktail against the SARS-CoV-2 Omicron variant, demonstrating comparable potency to GSK/Vir's sotrovimab. The tests conducted at Boston University and Washington University confirmed that the combination of IMM20253 and IMM20184 neutralized Omicron with an IC50 of 27 nM. The cocktail employs a novel mechanism that enhances viral resistance, targeting the spike protein's ACE2 binding site. Moving forward, Immunome plans to advance its program into Phase 1b trials, supported by funding from the U.S. Department of Defense.
Immunome has received a clinical hold letter from the FDA regarding its IND submission for IMM-BCP-01, a three-antibody cocktail for COVID-19. The FDA has requested additional information about the cocktail's preparation and administration at clinical sites. Immunome intends to provide this information promptly and is still on track to report top-line clinical data for IMM-BCP-01 within the first half of 2022. Additionally, external laboratory tests for the cocktail's efficacy against the Omicron variant are expected this month.
Immunome, Inc. (Nasdaq: IMNM) will participate in a fireside chat hosted by Cantor Fitzgerald's Brian Cheng on December 8, 2021, at 1:00 p.m. ET, aimed at institutional clients. The event will be accessible via webcast, with a replay available on Immunome's website for 30 days following the live presentation.
Immunome utilizes its proprietary human memory B cell platform to develop innovative antibody therapeutics focusing on oncology and infectious diseases, including COVID-19.
Immunome expects its antibody cocktail, IMM-BCP-01, to be effective against the Omicron variant of SARS-CoV-2. The company is performing laboratory testing to confirm this, with results anticipated in January 2022. IMM-BCP-01 targets three distinct epitopes, enhancing its potential resilience against mutations. The cocktail approach aims to improve viral neutralization, as demonstrated in preclinical tests against other variants. Immunome is advancing IMM-BCP-01 towards clinical trials, pending regulatory approval.
Immunome, Inc. (NASDAQ: IMNM) has submitted an Investigational New Drug (IND) application to the U.S. FDA for IMM-BCP-01, a novel three-antibody cocktail targeting SARS-CoV-2. This submission marks a significant milestone for Immunome as they prepare to conduct clinical studies. Preclinical testing shows that IMM-BCP-01 effectively reduces viral load and encompasses broad coverage against various COVID-19 variants. The project is funded by the U.S. Department of Defense, emphasizing its public health importance as COVID-19 continues to pose a threat.
Immunome, Inc. (Nasdaq: IMNM) made progress in its antibody development, notably with IMM-BCP-01, targeting SARS-CoV-2 variants Lambda and Delta Plus. The company plans to submit an IND for IMM-BCP-01 this quarter, alongside anticipated topline data in H1 2022. Financially, for Q3 2021, R&D expenses reached $4.5M, while G&A expenses were $3.2M, leading to a net loss of $7.7M. As of September 30, 2021, cash reserves stood at $56.3M, indicating sufficient resources for ongoing projects.